[68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas

Nika Guberina; Lukas Kessler; Christoph Pöttgen; Maja Guberina; Martin Metzenmacher; Ken Herrmann; Maja Mucha; Christoph Rischpler; Frank Indenkämpen; Jens T. Siveke; Jürgen Treckmann; Lale Umutlu; Stefan Kasper; Wolfgang P. Fendler; Martin Stuschke

doi:10.1038/s41598-022-20447-6

[⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas

Nika Guberina
, Lukas Kessler
, Christoph Pöttgen
, Maja Guberina
, Martin Metzenmacher
, Ken Herrmann
, Maja Mucha
, Christoph Rischpler
, Frank Indenkämpen
, Jens T. Siveke
, Jürgen Treckmann
, Lale Umutlu
, Stefan Kasper
, Wolfgang P. Fendler
, Martin Stuschke

University Hospital of Essen
University of Duisburg-Essen
German Cancer Research Center

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

12 Zitate (Scopus)

Abstract

Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[⁶⁸Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[⁶⁸Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[⁶⁸Ga]FAPI-PET/CT±[¹⁸F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUV_max were separately generated based on [⁶⁸Ga]FAPI- and [¹⁸F]FDG-PET/CT-images. A [⁶⁸Ga]FAPI- and [¹⁸F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [⁶⁸Ga]FAPI-PET/CT and [¹⁸F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUV_{max_lesion}/SUV_{mean_background}] for individual timepoints t₁ and t₂ revealed significant higher values for [⁶⁸Ga]FAPI compared to [¹⁸F]FDG (t₁, p = 0.008; t₂, p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [⁶⁸Ga]FAPI-based planning resulted in D100% = 97.2% and V95% = 98.8% for the [¹⁸F]FDG-MTV. [¹⁸F]FDG-based-planning resulted in D100% = 35.9% and V95% = 78.1% for [⁶⁸Ga]FAPI-MTV. [¹⁸F]FDG-based-planning resulted only in 2 patients in V95% > 95% for [⁶⁸Ga]FAPI-MTV, and in 1 patient in D100% > 97% for [⁶⁸Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [¹⁸F]FDG-based-planning and 99.5% by [⁶⁸Ga]FAPI-based-planning. Pretreatment [⁶⁸Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [¹⁸F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [⁶⁸Ga]FAPI-imaging. Complementary [⁶⁸Ga]FAPI- and [¹⁸F]FDG-imaging enhance treatment-response-assessment.

Originalsprache	Englisch
Aufsatznummer	16261
Fachzeitschrift	Scientific Reports
Jahrgang	12
Ausgabenummer	1
DOIs	https://doi.org/10.1038/s41598-022-20447-6
Publikationsstatus	Veröffentlicht - Dez. 2022
Extern publiziert	Ja

Zugriff auf Dokument

10.1038/s41598-022-20447-6

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Guberina, N., Kessler, L., Pöttgen, C., Guberina, M., Metzenmacher, M., Herrmann, K., Mucha, M., Rischpler, C., Indenkämpen, F., Siveke, J. T., Treckmann, J., Umutlu, L., Kasper, S., Fendler, W. P., & Stuschke, M. (2022). [⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas. Scientific Reports, 12(1), Artikel 16261. https://doi.org/10.1038/s41598-022-20447-6

@article{dbbaf016f6e74313b9962d31e79510b6,

title = "[68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas",

abstract = "Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[68Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[68Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[68Ga]FAPI-PET/CT±[18F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUVmax were separately generated based on [68Ga]FAPI- and [18F]FDG-PET/CT-images. A [68Ga]FAPI- and [18F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [68Ga]FAPI-PET/CT and [18F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUVmax\_lesion/SUVmean\_background] for individual timepoints t1 and t2 revealed significant higher values for [68Ga]FAPI compared to [18F]FDG (t1, p = 0.008; t2, p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [68Ga]FAPI-based planning resulted in D100\% = 97.2\% and V95\% = 98.8\% for the [18F]FDG-MTV. [18F]FDG-based-planning resulted in D100\% = 35.9\% and V95\% = 78.1\% for [68Ga]FAPI-MTV. [18F]FDG-based-planning resulted only in 2 patients in V95\% > 95\% for [68Ga]FAPI-MTV, and in 1 patient in D100\% > 97\% for [68Ga]FAPI-MTV. GTV-coverage in terms of V95\% was 76.4\% by [18F]FDG-based-planning and 99.5\% by [68Ga]FAPI-based-planning. Pretreatment [68Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [18F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [68Ga]FAPI-imaging. Complementary [68Ga]FAPI- and [18F]FDG-imaging enhance treatment-response-assessment.",

author = "Nika Guberina and Lukas Kessler and Christoph P{\"o}ttgen and Maja Guberina and Martin Metzenmacher and Ken Herrmann and Maja Mucha and Christoph Rischpler and Frank Indenk{\"a}mpen and Siveke, \{Jens T.\} and J{\"u}rgen Treckmann and Lale Umutlu and Stefan Kasper and Fendler, \{Wolfgang P.\} and Martin Stuschke",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41598-022-20447-6",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Guberina, N, Kessler, L, Pöttgen, C, Guberina, M, Metzenmacher, M, Herrmann, K, Mucha, M, Rischpler, C, Indenkämpen, F, Siveke, JT, Treckmann, J, Umutlu, L, Kasper, S, Fendler, WP & Stuschke, M 2022, '[⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas', Scientific Reports, Jg. 12, Nr. 1, 16261. https://doi.org/10.1038/s41598-022-20447-6

TY - JOUR

T1 - [68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas

AU - Guberina, Nika

AU - Kessler, Lukas

AU - Pöttgen, Christoph

AU - Guberina, Maja

AU - Metzenmacher, Martin

AU - Herrmann, Ken

AU - Mucha, Maja

AU - Rischpler, Christoph

AU - Indenkämpen, Frank

AU - Siveke, Jens T.

AU - Treckmann, Jürgen

AU - Umutlu, Lale

AU - Kasper, Stefan

AU - Fendler, Wolfgang P.

AU - Stuschke, Martin

PY - 2022/12

Y1 - 2022/12

N2 - Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[68Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[68Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[68Ga]FAPI-PET/CT±[18F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUVmax were separately generated based on [68Ga]FAPI- and [18F]FDG-PET/CT-images. A [68Ga]FAPI- and [18F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [68Ga]FAPI-PET/CT and [18F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUVmax_lesion/SUVmean_background] for individual timepoints t1 and t2 revealed significant higher values for [68Ga]FAPI compared to [18F]FDG (t1, p = 0.008; t2, p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [68Ga]FAPI-based planning resulted in D100% = 97.2% and V95% = 98.8% for the [18F]FDG-MTV. [18F]FDG-based-planning resulted in D100% = 35.9% and V95% = 78.1% for [68Ga]FAPI-MTV. [18F]FDG-based-planning resulted only in 2 patients in V95% > 95% for [68Ga]FAPI-MTV, and in 1 patient in D100% > 97% for [68Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [18F]FDG-based-planning and 99.5% by [68Ga]FAPI-based-planning. Pretreatment [68Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [18F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [68Ga]FAPI-imaging. Complementary [68Ga]FAPI- and [18F]FDG-imaging enhance treatment-response-assessment.

AB - Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[68Ga]FAPI-PET/CT on target-volume-definition and posttreatment-[68Ga]FAPI-PET/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[68Ga]FAPI-PET/CT±[18F]FDG-PET/CT were included from 01.01.2020 to 01.03.2022. MTV and SUVmax were separately generated based on [68Ga]FAPI- and [18F]FDG-PET/CT-images. A [68Ga]FAPI- and [18F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [68Ga]FAPI-PET/CT and [18F]FDG-PET/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUVmax_lesion/SUVmean_background] for individual timepoints t1 and t2 revealed significant higher values for [68Ga]FAPI compared to [18F]FDG (t1, p = 0.008; t2, p = 0.005). Intermodality comparison of radiation-therapy-plans showed that [68Ga]FAPI-based planning resulted in D100% = 97.2% and V95% = 98.8% for the [18F]FDG-MTV. [18F]FDG-based-planning resulted in D100% = 35.9% and V95% = 78.1% for [68Ga]FAPI-MTV. [18F]FDG-based-planning resulted only in 2 patients in V95% > 95% for [68Ga]FAPI-MTV, and in 1 patient in D100% > 97% for [68Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [18F]FDG-based-planning and 99.5% by [68Ga]FAPI-based-planning. Pretreatment [68Ga]FAPI-PET/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [18F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [68Ga]FAPI-imaging. Complementary [68Ga]FAPI- and [18F]FDG-imaging enhance treatment-response-assessment.

UR - https://www.scopus.com/pages/publications/85138875071

U2 - 10.1038/s41598-022-20447-6

DO - 10.1038/s41598-022-20447-6

M3 - Article

C2 - 36171444

AN - SCOPUS:85138875071

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 16261